바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.80 No.3
Citation Share

Evaluation of Appropriate Management of Chronic Obstructive Pulmonary Disease in Korea: Based on Health Insurance Review and Assessment Service (HIRA) Claims

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2017, v.80 no.3, pp.241-246


& (2017). Evaluation of Appropriate Management of Chronic Obstructive Pulmonary Disease in Korea: Based on Health Insurance Review and Assessment Service (HIRA) Claims. Tuberculosis & Respiratory Diseases, 80(3), 241-246.
  • Downloaded
  • Viewed
PDF Download

Abstract

Chronic obstructive pulmonary disease (COPD) is an ambulatory care-sensitive condition, and effective treatment of outpatients can prevent worsening of the illness and hospitalization. Current COPD guidelines provide appropriate guidance for the diagnosis and treatment of patients with COPD. In fact, it has been shown that when appropriate guidance and treatment are performed, the morbidity and mortality rates of COPD patients are reduced. However, there is a gap between the clinical guidelines and the actual clinical treatment. Therefore, the Health Insurance Review and Assessment Service (HIRA) conducted an evaluation of the adequacy of COPD diagnosis and treatment using the Claims Database of HIRA. This review provides a summary of the COPD adequacy assessment results reported by the HIRA and some brief comments on the results.

keywords
Pulmonary Disease, Chronic Obstructive, Insurance, Health

Reference

1.

1. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea:the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-65.

2.

2. Lee J, Lee JH, Kim JA, Rhee CK. Trend of cost and utilization of COPD medication in Korea. Int J Chron Obstruct Pulmon Dis 2017;12:27-33.

3.

3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.

4.

4. Lee JY, Rhee CK, Jung KS, Yoo KH. Strategies for management of the early chronic obstructive lung disease. Tuberc Respir Dis 2016;79:121-6.

5.

5. Organisation for Economic Co-operation and Development. Health at a glance 2015: OECD indicators. Paris: OECD; 2015.

6.

6. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J 2017;49:1700214.

7.

7. Health Insurance Review & Assessment Service. Evaluation of appropriate management of COPD in Korea 2017 [Internet]. Wonju: Health Insurance Review & Assessment Service; 2017[cited 2017 May 1]. Available from: http://www.hira.or.kr/re/diag/getDiagEvlList.do?pgmid=HIRAA030004000000&WT. ac=%EB%B3%91%EC%9B%90%ED%8F%89%EA%B0%80.

8.

8. Beeh KM. The role of bronchodilators in preventing exacerbations of chronic obstructive pulmonary disease. Tuberc Respir Dis 2016;79:241-7.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy